Brief: Positive results from Replicel's RCS-01 phase I skin trial are the Company's most compelling to date
04/04/2017 11:00
April 4 (Reuters) - Replicel Life Sciences Inc RP.V
* Positive results from Replicel's RCS-01 phase I skin trial
are the company's most compelling to date
* Interim trial results lead researchers to conclude that
injection of RCS-01 is not only very safe, but also has
potential to reverse effects of aging skin
Source text for Eikon: ID:nCNWcykTla
Further company coverage: RP.V
((Bangalore.newsroom@thomsonreuters.com;))
Recent news on Replicel Life Sciences
See all newsBrief: Replicel Life Sciences Announces Reinstatement Of Trading & Conditional Acceptance For Proposed Transaction
Brief: Replicel Life Sciences Says Replicel Announces A Letter Of Intent For Asset Purchase Agreement
Brief: Replicel Announces Binding Term Sheet For Strategic Investment And U.S. Partnership
Brief: Replicel Announces Its Incoming Board Of Directors
Brief: RepliCel Life Sciences Retains Dermatology Sales And Marketing Executive To Guide Global Commercial Strategy For Automated Dermal Injector